Redeye comments on Hansa Biopharma's Q4 report. Revenues were SEK35m (SEK66m). IDEFIRIX sales amounted to SEK34m. This was a significant decline Y/Y and Q/Q and below our forecast, although we had expected a soft quarter. However, several improvements in the commercial landscape and near-term data readouts position the company for growth in Europe for the full year 2026. We believe the current low share price creates an attractive entry point, both for short- and long-term investors.
LÄS MER
